Clicky

Genmab A/S(GMAB)

Description: Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Drugs Immunology Solid Tumors Antibodies Treatment Of Cancer Monoclonal Antibodies Parkinson's Disease Lymphoma Monoclonal Antibody Non Small Cell Lung Cancer Immunotherapies Acute Myeloid Leukemia Multiple Sclerosis Genetics Multiple Myeloma Breakthrough Therapy Copenhagen Amyloidosis Antibody Drug Conjugate Chronic Lymphocytic Leukemia Orphan Drug Amyloid Lymphocytic Leukemia Genmab Solid Cancers Advanced Cancer Camidanlumab Tesirine Treatment Of Chronic Lymphocytic Leukemia Advanced Cancers Cd20

Home Page: www.genmab.com

GMAB Technical Analysis

Kalvebod Brygge 43
Copenhagen, 1560
Denmark
Phone: 45 70 20 27 28


Officers

Name Title
Dr. Jan G.J. van de Winkel Ph.D. Co-Founder, Pres & CEO
Mr. Anthony Pagano Exec. VP & CFO
Mr. Anthony Mancini Exec. VP & COO
Dr. Judith V. Klimovsky M.D. Exec. VP & Chief Devel. Officer
Dr. Tahamtan Ahmadi Exec. VP, Chief Medical Officer & Head of Experimental Medicines
Dr. Mijke Zachariasse Ph.D. Director of Protein Production & Chemist and Non-Independent Director
Dr. Rima Bawarshi Nassar Ph.D. VP, Head of Global Regulatory Affairs ? Oncology & Non-Independent Director
Mr. Peter Ros Sr. Director of Fin. & Accounting
Mr. Andrew Carlsen Sr. Director, VP & Head of Investor Relations
Ms. Birgitte Stephensen M.Sc. Exec. VP & Chief Legal Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 35.3357
Trailing PE: 35.7417
Price-to-Book MRQ: 8.0051
Price-to-Sales TTM: 2.463
IPO Date: 2009-06-01
Fiscal Year End: December
Full Time Employees: 1560
Back to stocks